1. Home
  2. VOD vs ONC Comparison

VOD vs ONC Comparison

Compare VOD & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vodafone Group Plc

VOD

Vodafone Group Plc

HOLD

Current Price

$14.72

Market Cap

33.1B

ML Signal

HOLD

ONC

BeiGene Ltd. American Depositary Shares

HOLD

Current Price

$283.68

Market Cap

33.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VOD
ONC
Founded
1984
2010
Country
United Kingdom
Switzerland
Employees
86702
12000
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.1B
33.5B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
VOD
ONC
Price
$14.72
$283.68
Analyst Decision
Sell
Strong Buy
Analyst Count
3
11
Target Price
N/A
$377.91
AVG Volume (30 Days)
3.5M
242.6K
Earning Date
11-14-2025
05-06-2026
Dividend Yield
3.39%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$11.65
$759.19
Revenue Next Year
$5.40
$14.51
P/E Ratio
N/A
$614.06
Revenue Growth
N/A
N/A
52 Week Low
$8.05
$196.53
52 Week High
$15.91
$385.22

Technical Indicators

Market Signals
Indicator
VOD
ONC
Relative Strength Index (RSI) 50.99 35.73
Support Level $14.56 $239.25
Resistance Level $14.81 $284.51
Average True Range (ATR) 0.25 6.68
MACD -0.00 -0.50
Stochastic Oscillator 86.29 29.74

Price Performance

Historical Comparison
VOD
ONC

About VOD Vodafone Group Plc

Vodafone operates mobile and fixed-line networks and businesses across Europe, Africa, and the Middle East. Its largest market is Germany, where it is the second mobile operator after Deutsche Telekom and owns two cable network after acquiring Kabel Deutschland in 2013 and Liberty Global Germany in 2019. In the UK Vodafone merger with CK Hutchison in 2024, consolidating the mobile market. It also divested its Spanish and Italian divisions in that same year, given their low returns on invested capital.

About ONC BeiGene Ltd. American Depositary Shares

BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.

Share on Social Networks: